Form 4: Vera Therapeutics SVP Acquires 10,000 Shares via Option Exercise

Vera Therapeutics' SVP of Finance and Chief Accounting Officer, Joseph R. Young, acquired 10,000 shares of Class A Common Stock through an option exercise and additional shares via an Employee Stock Purchase Plan.

Summary

• Joseph R. Young, SVP, Finance, and Chief Accounting Officer of Vera Therapeutics, Inc. (VERA), acquired 10,000 shares of Class A Common Stock.
• The acquisition occurred on March 13, 2026, through the exercise of a stock option at an exercise price of $3.9396 per share.
• An additional 1,032 shares were acquired pursuant to the Company's 2021 Employee Stock Purchase Plan.
• Following these transactions, Mr. Young directly beneficially owns 75,754 shares of Class A Common Stock.
• He also holds 38,589 unexercised stock options with an exercise price of $3.9396, expiring on April 13, 2031.
• The options' vesting schedule indicates 1/4 of the shares vested on March 9, 2022, with 1/48 vesting monthly thereafter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. An executive increasing their direct ownership, even through compensation-related mechanisms, generally indicates confidence in the company's long-term value and aligns management interests with shareholders.

Positives

• An executive acquiring shares, especially through option exercise, can signal confidence in the company's future prospects.
• The acquisition of 1,032 shares through the Employee Stock Purchase Plan demonstrates ongoing participation and alignment with shareholder interests.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedule of the stock options and their expiration date.

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises and ESPP participation, are common compensation mechanisms in the biotechnology and pharmaceutical industries. While this specific transaction is routine, it reflects an executive's continued stake in the company's performance, which is a standard practice across the sector.

Related Party Transactions

• The exercise of stock options and acquisition of shares through the Employee Stock Purchase Plan by a senior officer (Joseph R. Young) are considered related party transactions as they involve an insider and the company.

Stakeholder Impact

• Shareholders: The increase in insider ownership may be viewed positively as it aligns management's interests with those of shareholders, potentially signaling confidence in future performance.
• Employees: The Employee Stock Purchase Plan (ESPP) indicates a benefit program available to employees, fostering broader employee ownership and engagement.

Next Steps

• The remaining 38,589 stock options will continue to vest monthly, with 1/48 of the shares vesting each month.
• The remaining stock options held by Joseph R. Young will expire on April 13, 2031, if not exercised prior.

Key Dates

Recommendation

While the insider acquisition of shares is a positive signal of management confidence, this Form 4 filing primarily details a routine compensation-related transaction. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change from a 'hold' position without further analysis of the company's broader financial health and market conditions.

Keywords

Vera Therapeutics, VERA, Joseph R. Young, Insider Trading, Stock Option Exercise, Employee Stock Purchase Plan, SEC Form 4, Beneficial Ownership, Class A Common Stock